UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 56

Sortiert nach

Role of Nox4 and Nox2 in hyperoxia-induced reactive oxygen species generation and migration of human lung endothelial cells

Antioxidants & redox signaling, 2009-04, Vol.11 (4), p.747

2009

Link zum Volltext

Verfügbarkeit prüfen

Nrf2 regulates hyperoxia-induced Nox4 expression in human lung endothelium: Identification of functional antioxidant response elements on the Nox4 promoter

Free radical biology & medicine, 2011-06, Vol.50 (12), p.1749-1759

2011

Link zum Volltext

Verfügbarkeit prüfen

Protection of LPS-induced murine acute lung injury by sphingosine-1-phosphate lyase suppression

American journal of respiratory cell and molecular biology, 2011-08, Vol.45 (2), p.426-435

2011

Link zum Volltext

Verfügbarkeit prüfen

Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)

Respiratory research, 2019-10, Vol.20 (1), p.241-241, Article 241

2019

Link zum Volltext

Verfügbarkeit prüfen

FoxM1 mediates the progenitor function of type II epithelial cells in repairing alveolar injury induced by Pseudomonas aeruginosa

The Journal of experimental medicine, 2011-07, Vol.208 (7), p.1473-1484

2011

Link zum Volltext

Verfügbarkeit prüfen

Regulation of NADPH oxidase in vascular endothelium: the role of phospholipases, protein kinases, and cytoskeletal proteins

Antioxidants & redox signaling, 2009-04, Vol.11 (4), p.841

2009

Link zum Volltext

Verfügbarkeit prüfen

Role of lysophosphatidic acid receptor LPA2 in the development of allergic airway inflammation in a murine model of asthma

Respiratory research, 2009-11, Vol.10 (1), p.114-114, Article 114

2009

Link zum Volltext

Verfügbarkeit prüfen

Trials in Progress: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trials of a Nebulized Long-Acting Muscarinic Antagonist (Revefenacin) in Study Participants With Moderate to Very Severe COPD

Chest, 2016-10, Vol.150 (4), p.825A-825A

2016

Link zum Volltext

Verfügbarkeit prüfen

Trial in Progress: A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trial to Evaluate the Safety and Tolerability of a Nebulized Long-Acting Muscarinic Antagonist (Revefenacin) in Study Participants With COPD

Chest, 2016-10, Vol.150 (4), p.866A-866A

2016

Link zum Volltext

Verfügbarkeit prüfen

Redox regulation of Nox proteins

Respiratory physiology & neurobiology, 2010-12, Vol.174 (3), p.265-271

2010

Link zum Volltext

Verfügbarkeit prüfen

Coronin 1B regulates S1P-induced human lung endothelial cell chemotaxis: role of PLD2, protein kinase C and Rac1 signal transduction

PloS one, 2013-05, Vol.8 (5), p.e63007

2013

Link zum Volltext

Verfügbarkeit prüfen

Dynamin 2 and c-Abl Are Novel Regulators of Hyperoxia-mediated NADPH Oxidase Activation and Reactive Oxygen Species Production in Caveolin-enriched Microdomains of the Endothelium

The Journal of biological chemistry, 2009-12, Vol.284 (50), p.34964-34975

2009

Link zum Volltext

Verfügbarkeit prüfen

Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation

PloS one, 2012-09, Vol.7 (9), p.e45330-e45330

2012

Link zum Volltext

Verfügbarkeit prüfen

Regulation of Hyperoxia-induced NADPH Oxidase Activation in Human Lung Endothelial Cells by the Actin Cytoskeleton and Cortactin

The Journal of biological chemistry, 2007-08, Vol.282 (32), p.23284-23295

2007

Link zum Volltext

Verfügbarkeit prüfen

Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease

Data in brief, 2019-10, Vol.26, p.104277-104277, Article 104277

2019

Link zum Volltext

Verfügbarkeit prüfen

EFFICACY OF REVEFENACIN, A LONG-ACTING MUSCARINIC ANTAGONIST FOR NEBULIZED THERAPY, IN COPD PATIENTS WITH MARKERS OF MORE SEVERE DISEASE

Chest, 2018-10, Vol.154 (4), p.736A-737A

2018

Link zum Volltext

Verfügbarkeit prüfen

26991 A decade to diagnose, a lifetime to treat: The time burden associated with basal cell carcinoma in patients with Gorlin syndrome

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB125-AB125

2021

Link zum Volltext

Verfügbarkeit prüfen

The 24-Hour Profile of FEV 1 After 12-Weeks Treatment With Revefenacin, a Once Daily Long-Acting Muscarinic Receptor Antagonists for Nebulization: A Spirometry Substudy

Chest, 2017-10, Vol.152 (4), p.A770

2017

Link zum Volltext

Verfügbarkeit prüfen

The 24-Hour Profile of FEV1 After 12-Weeks Treatment With Revefenacin, a Once Daily Long-Acting Muscarinic Receptor Antagonists for Nebulization: A Spirometry Substudy

Chest, 2017-10, Vol.152 (4), p.A770-A770

2017

Link zum Volltext

Verfügbarkeit prüfen

Improvements in Health Status With Revefenacin, a Once-Daily Long-Acting Muscarinic Antagonist for Nebulization: Changes in St George’s Respiratory Questionnaire and COPD Assessment Test in Replicate 3-Month Studies

Chest, 2017-10, Vol.152 (4), p.A819-A819

2017

Link zum Volltext

Verfügbarkeit prüfen

NOX enzymes and pulmonary disease

Antioxidants & redox signaling, 2009-10, Vol.11 (10), p.2505

2009

Link zum Volltext

Verfügbarkeit prüfen

CARDIOVASCULAR SAFETY OF REVEFENACIN FOR NEBULIZATION: A REVIEW OF RANDOMIZED CONTROLLED TRIAL DATA

Chest, 2018-10, Vol.154 (4), p.734A-735A

2018

Link zum Volltext

Verfügbarkeit prüfen

EFFICACY OF REVEFENACIN BY NEBULIZATION AND TIOTROPIUM BY HANDIHALER IN SUBJECTS WITH COPD AND SUBOPTIMAL PEAK INSPIRATORY FLOW RATES (PIFR)

Chest, 2018-10, Vol.154 (4), p.732A-733A

2018

Link zum Volltext

Verfügbarkeit prüfen

Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease

Respiratory medicine, 2019-07, Vol.153, p.38-43

2019

Link zum Volltext

Verfügbarkeit prüfen

Targeting sphingosine kinase 1 attenuates bleomycin‐induced pulmonary fibrosis

The FASEB journal, 2013-04, Vol.27 (4), p.1749-1760

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(55)
Tagungsberichte
(1)

Sprache

Englisch
(56)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Science & Technology
(28)
Life Sciences & Biomedicine
(24)
Humans
(21)
Animals
(15)
Biochemistry & Molecular Biology
(11)
Mice
(11)
Reactive Oxygen Species - Metabolism
(11)
Mice, Knockout
(10)
Respiratory System
(10)
Cells, Cultured
(9)
Nadph Oxidases - Metabolism
(9)
Mice, Inbred C57bl
(8)
Male
(7)
Revefenacin
(7)
Lung - Metabolism
(6)
Rna, Small Interfering - Genetics
(6)
Sphingosine - Analogs & Derivatives
(6)
Cell Biology
(5)
Enzyme Activation
(5)
Female
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Role of Nox4 and Nox2 in hyperoxia-induced reactive oxygen species generation and migration of human lung endothelial cells

Nrf2 regulates hyperoxia-induced Nox4 expression in human lung endothelium: Identification of functional antioxidant response elements on the Nox4 promoter

Protection of LPS-induced murine acute lung injury by sphingosine-1-phosphate lyase suppression

Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)

FoxM1 mediates the progenitor function of type II epithelial cells in repairing alveolar injury induced by Pseudomonas aeruginosa

Regulation of NADPH oxidase in vascular endothelium: the role of phospholipases, protein kinases, and cytoskeletal proteins

Role of lysophosphatidic acid receptor LPA2 in the development of allergic airway inflammation in a murine model of asthma

Trials in Progress: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trials of a Nebulized Long-Acting Muscarinic Antagonist (Revefenacin) in Study Participants With Moderate to Very Severe COPD

Trial in Progress: A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trial to Evaluate the Safety and Tolerability of a Nebulized Long-Acting Muscarinic Antagonist (Revefenacin) in Study Participants With COPD

Redox regulation of Nox proteins

Coronin 1B regulates S1P-induced human lung endothelial cell chemotaxis: role of PLD2, protein kinase C and Rac1 signal transduction

Dynamin 2 and c-Abl Are Novel Regulators of Hyperoxia-mediated NADPH Oxidase Activation and Reactive Oxygen Species Production in Caveolin-enriched Microdomains of the Endothelium

Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation

Regulation of Hyperoxia-induced NADPH Oxidase Activation in Human Lung Endothelial Cells by the Actin Cytoskeleton and Cortactin

Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease

EFFICACY OF REVEFENACIN, A LONG-ACTING MUSCARINIC ANTAGONIST FOR NEBULIZED THERAPY, IN COPD PATIENTS WITH MARKERS OF MORE SEVERE DISEASE

26991 A decade to diagnose, a lifetime to treat: The time burden associated with basal cell carcinoma in patients with Gorlin syndrome

The 24-Hour Profile of FEV 1 After 12-Weeks Treatment With Revefenacin, a Once Daily Long-Acting Muscarinic Receptor Antagonists for Nebulization: A Spirometry Substudy

The 24-Hour Profile of FEV1 After 12-Weeks Treatment With Revefenacin, a Once Daily Long-Acting Muscarinic Receptor Antagonists for Nebulization: A Spirometry Substudy

Improvements in Health Status With Revefenacin, a Once-Daily Long-Acting Muscarinic Antagonist for Nebulization: Changes in St George’s Respiratory Questionnaire and COPD Assessment Test in Replicate 3-Month Studies

NOX enzymes and pulmonary disease

CARDIOVASCULAR SAFETY OF REVEFENACIN FOR NEBULIZATION: A REVIEW OF RANDOMIZED CONTROLLED TRIAL DATA

EFFICACY OF REVEFENACIN BY NEBULIZATION AND TIOTROPIUM BY HANDIHALER IN SUBJECTS WITH COPD AND SUBOPTIMAL PEAK INSPIRATORY FLOW RATES (PIFR)

Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease

Targeting sphingosine kinase 1 attenuates bleomycin‐induced pulmonary fibrosis

Suchergebnisse filtern